Cognition Therapeutics (CGTX) Common Equity (2020 - 2026)

Cognition Therapeutics (CGTX) has 7 years of Common Equity data on file, last reported at $29.9 million in Q1 2026.

• Quarterly Common Equity rose 143.77% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.9 million (up 143.77% YoY) and the FY2025 annual result came in at $34.3 million, up 82.78% from the prior year.
• Common Equity eased to $29.9 million in Q1 2026 per CGTX's latest filing, from $34.3 million in the prior quarter.
• Across five years, Common Equity topped out at $48.7 million in Q1 2022 and bottomed at $7.0 million in Q2 2025.
• The 5-year median for Common Equity is $29.9 million (2026), against an average of $29.5 million.
• The widest annual swing landed in 2022, when Common Equity jumped 171.83%; it then tumbled 69.45% in 2025.
• Tracing CGTX's Common Equity over 5 years: stood at $40.2 million in 2022, then tumbled by 39.19% to $24.5 million in 2023, then declined by 23.39% to $18.8 million in 2024, then surged by 82.78% to $34.3 million in 2025, then slipped by 12.72% to $29.9 million in 2026.
• Per Business Quant, the three latest CGTX Common Equity figures stand at $29.9 million (Q1 2026), $34.3 million (Q4 2025), and $36.5 million (Q3 2025).

Peer Comparison